{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:16Z","timestamp":1753891276538,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis. Portal venous system thrombosis (PVST) is a major complication of liver cirrhosis. Recently, it has been shown that C-type lectin-like receptor 2 (CLEC-2) and galectin-1 participate in the activation and aggregation of platelets, thereby promoting the development of thrombosis. This cross-sectional study aims to evaluate the association of serum CLEC-2 and galectin-1 levels with PVST in patients with HBV-related liver cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Overall, 65 patients with HBV-related liver cirrhosis were included, of whom 23 had PVST and 42 did not have. Serum CLEC-2 and galectin-1 levels were measured using enzyme-linked immunosorbent assay kits. PVST was assessed by contrast-enhanced computed tomography and\/or magnetic resonance imaging scans. Subgroup analyses were conducted according to the degree and location of PVST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with PVST had significantly higher serum CLEC-2 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006) and galectin-1 (<jats:italic>p<\/jats:italic> =\u20090.009) levels than those without. Patients with partial\/complete PVST or fibrotic cord (<jats:italic>p<\/jats:italic> =\u20090.007; <jats:italic>p<\/jats:italic> =\u20090.002), but not those with mural PVST (<jats:italic>p<\/jats:italic> =\u20090.199; <jats:italic>p<\/jats:italic> =\u20090.797), had significantly higher serum CLEC-2 and galectin-1 levels than those without PVST. Patients with superior mesenteric vein thrombosis had significantly higher serum CLEC-2 (<jats:italic>p<\/jats:italic> =\u20090.013) and galectin-1 (<jats:italic>p<\/jats:italic> =\u20090.025) levels than those without PVST. Patients with main portal vein thrombosis had higher serum CLEC-2 (<jats:italic>p<\/jats:italic> =\u20090.020) and galectin-1 (<jats:italic>p<\/jats:italic> =\u20090.066) levels than those without PVST, but the difference in serum galectin-1 level was not significant between them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum CLEC-2 and galectin-1 levels may be associated with the presence of PVST in HBV-related cirrhotic patients, but this association should be dependent upon the degree of PVST.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1228636","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:50:13Z","timestamp":1693482613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of C-type lectin-like receptor 2 and galectin-1 with portal vein system thrombosis in HBV-related liver cirrhosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Yiyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoze","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.2174\/1389450117666160613101413","article-title":"Recent advancements in diagnosis and therapy of liver cirrhosis","volume":"17","author":"Romanelli","year":"2016","journal-title":"Curr Drug Targets"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.20524\/aog.2018.0245","article-title":"Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges","volume":"31","author":"Mantaka","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1751-2980.12970","article-title":"Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)","volume":"22","year":"2021","journal-title":"J Dig Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/09537104.2021.1906407","article-title":"The structure of CLEC-2: mechanisms of dimerization and higher-order clustering","volume":"32","author":"Martin","year":"2021","journal-title":"Platelets"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3109\/09537104.2011.556274","article-title":"The novel platelet activation receptor CLEC-2","volume":"22","author":"Suzuki-Inoue","year":"2011","journal-title":"Platelets"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1055\/a-1896-6992","article-title":"CLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear","volume":"122","author":"Bourne","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"688643","DOI":"10.3389\/fimmu.2021.688643","article-title":"The role of CLEC-2 and its ligands in Thromboinflammation","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1182\/blood-2009-05-222273","article-title":"CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis","volume":"114","author":"May","year":"2009","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2016-09-742999","article-title":"Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis","volume":"129","author":"Payne","year":"2017","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/glycob\/cwp077","article-title":"Galectin-1 stimulates monocyte chemotaxis via the p44\/42 MAP kinase pathway and a pertussis toxin-sensitive pathway","volume":"19","author":"Malik","year":"2009","journal-title":"Glycobiology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"137r","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: a small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1600-0854.2005.00302.x","article-title":"Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells","volume":"6","author":"Nickel","year":"2005","journal-title":"Traffic (Copenhagen, Denmark)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1096\/fj.11-197541","article-title":"Binding of galectin-1 to \u03b1IIb\u03b2\u2083 integrin triggers \"outside-in\" signals, stimulates platelet activation, and controls primary hemostasis","volume":"26","author":"Romaniuk","year":"2012","journal-title":"FASEB J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1182\/blood-2009-08-237834","article-title":"CLEC-2 activates Syk through dimerization","volume":"115","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1055\/s-0039-3400295","article-title":"A comprehensive tyrosine Phosphoproteomic analysis reveals novel components of the platelet CLEC-2 Signaling Cascade","volume":"120","author":"Izquierdo","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11684-019-0692-x","article-title":"Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease","volume":"14","author":"Fei","year":"2020","journal-title":"Front. Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/STROKEAHA.118.022563","article-title":"Prognostic significance of plasma CLEC-2 (C-type lectin-like receptor 2) in patients with acute ischemic stroke","volume":"50","author":"Zhang","year":"2019","journal-title":"Stroke"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1055\/s-0042-1756648","article-title":"Impact of asymptomatic superior mesenteric vein thrombosis on the outcomes of patients with liver cirrhosis","volume":"122","author":"Wang","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","article-title":"Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and Meta-analysis of observational studies","volume":"95","author":"Peng","year":"2016","journal-title":"Medicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1055\/s-2005-916671","article-title":"Platelets: physiology and biochemistry","volume":"31","author":"Jurk","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2008.09.010","article-title":"The platelet and platelet function testing in liver disease","volume":"13","author":"Hugenholtz","year":"2009","journal-title":"Clin Liver Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-016-0328-9","article-title":"Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients","volume":"35","author":"Zhao","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1055\/s-0039-1698829","article-title":"Platelets as central actors in thrombosis-reprising an old role and defining a new character","volume":"45","author":"Stevens","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1055\/s-0032-1305783","article-title":"Viral hepatitis and thrombosis: a narrative review","volume":"38","author":"Squizzato","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1499-3872(13)60081-8","article-title":"Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis","volume":"12","author":"Li","year":"2013","journal-title":"Hepatob Panc Dis Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"10988","DOI":"10.1021\/bi901427d","article-title":"The platelet receptor CLEC-2 is active as a dimer","volume":"48","author":"Watson","year":"2009","journal-title":"Biochemistry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coph.2008.11.001","article-title":"Thrombomodulation via CLEC-2 targeting","volume":"9","author":"O'Callaghan","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI122955","article-title":"Functional significance of the platelet immune receptors GPVI and CLEC-2","volume":"129","author":"Rayes","year":"2019","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/iub.483","article-title":"Identification of galectins as novel regulators of platelet signaling and function","volume":"63","author":"Romaniuk","year":"2011","journal-title":"IUBMB Life"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1161\/ATVBAHA.110.207522","article-title":"Signaling during platelet adhesion and activation","volume":"30","author":"Li","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1096\/fj.07-9524com","article-title":"The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation","volume":"22","author":"Pacienza","year":"2008","journal-title":"FASEB J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12891-021-04272-y","article-title":"Age-related trabecular bone loss is associated with a decline in serum Galectin-1 level","volume":"22","author":"Xu","year":"2021","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1228636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:50:16Z","timestamp":1693482616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1228636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":37,"alternative-id":["10.3389\/fmed.2023.1228636"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1228636","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1228636"}}